ACTRN12618000966291已完成1 期
A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled, Single-Ascending-Dose, 2-Way, Incomplete Block, 2-Period Crossover, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of 3 Doses of INP105 (olanzapine delivered by I231 POD® Device) Nasal Spray in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1) In good general health, with no significant medical history and no clinically significant abnormalities on physical examination at Screening or before first dose of IP;
- •2) Body mass index (BMI) between 18 and 32 kg/m2 inclusive;
- •3) Negative urine drug screen/alcohol breath test at Screening and Day -1;
- •4) The ability and willingness to attend the necessary visits at the study centre;
- •5) Written informed consent signed prior to entry into the study;
- •6) Female subjects of childbearing potential, and male subjects and their partners, must agree to use adequate contraception, defined as complete abstinence, documented evidence of surgical sterilization or condom plus approved contraceptive method.
排除标准
- •1) Known hypersensitivity to Zyprexa IM, Zyprexa Zydis or any of the ingredients in them or in INP105 or the placebo;
- •2) Recently (within 3 months) or currently taking Zyprexa (any formulation);
- •3) Participants taking medications known to inhibit or induce CYP1A2 at any time during the study period, and any participants taking prescription medications, over the counter medications or supplements that, in the opinion of the Investigator, may impact the subject’s response to olanzapine or impact the subject’s participation in the study. Oral contraceptives are permitted;
- •4) A medical history of hypotension or currently taking anti-hypertensives at Screening or throughout the study.
- •5) Current or recent smokers (< 3 months since quitting); inadvertent one-off smokers and social smokers will also be excluded;
- •6) Females who are pregnant or lactating;
- •7) Any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the subject will comply with the study;
- •8) Abnormal and clinically significant laboratory tests;
- •9) History or presence of alcohol or drug abuse within the 2 years prior to the first IP administration;
- •10) Blood donation or significant blood loss within 60 days prior to the first IP administration;
- •11) Plasma donation within 7 days prior to the first IP administration;
- •12) Administration of IP in another trial within 30 days or 5 half-lives (whichever is longer) prior to the first IP administration;
- •13) Significant surgery within the past 3 months prior to the first IP administration determined by the Investigator to be clinically relevant;
- •14) Failure to satisfy the Investigator of fitness to participate for any other reason;
- •15) Acute illness within 30 days prior to Day 1. Minor viral illnesses within 30 days prior to Day 1 may be randomized if all symptoms are resolved by admission and at the discretion of the Investigator;
- •16) Any nasal congestion, deviated septum or physical blockage in either nostril;
- •17) Positive for HIV, Hepatitis B or Hepatitis C.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Parallel-Group Study to Evaluate the Effect of LMTM on the Response to an Oral Tyramine Challenge and to Determine the Multiple-Dose Pharmacokinetics of LMTM.Alzheimers Diseasethinking and behaviortype of dementia that affects memory10042258NL-OMON51826TauRx Therapeutics Ltd.120
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GRX-917 in Healthy SubjectsMental Health - DepressionAnxietyACTRN12621000160831Gaba Therapeutics Australia Pty Ltd a subsidiary of Gaba Therapeutics, Inc102
已完成
1 期
A Study of Clofazimine Inhalation Suspension (MNKD-101) in Healthy VolunteersPulmonary Nontuberculous Mycobacteria InfectionsInfection - Other infectious diseasesACTRN12621001702808MannKind Corporation40
已完成
不适用
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Paltusotine In Healthy SubjectsacromegalyNL-OMON51860Crinetics Pharmaceuticals, Inc.27
已完成
1 期
A Phase 1, Placebo-controlled, First-in-human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses in Healthy SubjectsACTRN12621000592842Zhejiang Yao Yuan Biotechnology Ltd. (Drug Farm)50